World Sleep Industry ENCYCLOPEDIA

Hypoglossal Nerve Stimulation Implants

2.3.4

Definition, mechanism, and system architectures

A hypoglossal nerve stimulation implant activates selected motor branches that supply the tongue. Timed contraction of the genioglossus and other upper-airway dilator muscles can reduce pharyngeal collapse during obstructive sleep apnea. This is upper-airway neuromodulation, not brain stimulation and not respiratory pacing of the diaphragm. Benefit depends on forward movement and stiffening of the tongue and its mechanical coupling to the palate and lateral pharyngeal walls. Visible tongue movement near an electrode does not automatically establish that the entire airway has opened.

Architectures differ materially. One type combines a stimulation cuff around selected hypoglossal branches, an implanted pulse generator in the chest, and a sensing lead that detects respiratory effort so stimulation can be coordinated with inspiration. Another places a bilateral implant under the chin and receives wireless energy from an external unit attached to the skin each night, delivering programmed trains without the same chest generator and respiratory-sensing lead. Other platforms use multipolar stimulation leads and rechargeable generators. Unilateral and bilateral, respiration-synchronized and timed, fully implanted and externally powered systems are not interchangeable merely because all are called hypoglossal nerve stimulation.

The complete therapy chain may include the implant, leads and fixation components, clinician programmer, patient remote, charger, adhesive patch, mobile application, and sleep-laboratory software. A remote or patch is an external accessory rather than the implanted subject of this entry, yet a missing accessory, failed charging, or incorrect attachment can disable therapy. Products should be compared as complete systems with their intended use, indication, and validated parameters.

Candidacy, airway phenotype, and indication boundaries

These systems are intended for selected people with objectively diagnosed moderate-to-severe obstructive sleep apnea, generally after positive airway pressure has failed to control disease, cannot be tolerated, or is not appropriate under the product labeling. Age, apnea-hypopnea index range, body mass index, prior standard treatments, tonsillar anatomy, and craniofacial conditions differ by product and jurisdiction. A 2023 United States expansion for one system raised the baseline AHI ceiling to 100 and the recommended BMI ceiling to 40. Those boundaries do not transfer to another system or make every person within the numbers a candidate.

Screening confirms that events are predominantly obstructive; the proportion of central and mixed events must remain within the exact labeling because tongue stimulation does not correct deficient respiratory drive. Drug-induced sleep endoscopy characterizes collapse at the soft palate, lateral walls, tongue base, and epiglottis. Some unilateral systems exclude complete concentric palatal collapse, while evidence and labeling for other designs differ. BMI, neck circumference, and an awake examination cannot reliably replace endoscopic phenotype, and endoscopy itself is affected by sedation depth and scoring agreement.

Assessment also covers hypoglossal nerve function, prior neck surgery or radiation, fixed airway obstruction, severe lung or neuromuscular disease, coagulation and anesthesia risk, other implanted devices, pregnancy plans, and the ability to operate the remote or nightly accessories. The goal is reduction of obstruction, hypoxemia, and symptoms, not cessation of snoring alone. PAP optimization, mask problems, nasal resistance, an oral appliance, weight, and positional factors should receive a genuine review; intolerance should not be documented as a formality merely to qualify for implantation.

Implantation, nerve selection, and postoperative activation

A respiration-synchronized unilateral system commonly uses a neck incision to expose the hypoglossal nerve, identify branches that predominantly protrude the tongue, and place a stimulation cuff. A pulse generator is placed beneath chest skin and a sensing lead in the chest wall detects respiratory effort. An externally powered bilateral system may place electrode surfaces adjacent to left and right target branches through a submental incision and may not require a chest generator or respiratory lead. Incisions, components, and fixation are platform-specific and cannot be inferred from another design.

Branch selection determines the direction of tongue movement. Excess recruitment of fibers that retract the tongue can produce an unfavorable airway response. Intraoperative nerve monitoring, direct observation, and system testing help confirm selection but do not replace an all-night postoperative effectiveness study. Implantation must protect the hypoglossal nerve, vessels, submandibular and chest-wall structures, and pleura. A malpositioned sensing lead can produce timing error, and rare migration toward the pleural space or pneumothorax has been reported.

Activation occurs after an appropriate period for wound healing and neural recovery, followed by acclimatization and titration. Early surveillance includes bleeding, hematoma, infection, seroma, pneumothorax, swallowing or speech change, tongue weakness, and wound separation. Difficulty breathing, rapidly enlarging neck swelling, chest pain, substantial dyspnea, persistent tongue paralysis, or fever with drainage requires prompt assessment. Early swelling or altered sensation should not be countered by unsupervised increases in stimulation.

Programming, respiratory timing, and therapeutic titration

A prescription may define electrode or contact configuration, amplitude, pulse width, frequency, train duration and interval, start delay, pause duration, and the range of patient adjustment. A system with a respiratory sensor also requires detection thresholds and stimulation timing. An externally powered timed system depends on patch position, coupling, and a programmed rhythm. Producing the greatest possible tongue protrusion is not the goal; excessive stimulation can cause arousal, pain, swallowing discomfort, or abrasion where the tongue contacts teeth.

Initial programming observes comfort and tongue motion while awake, followed by assessment during sleep because supine position, lateral position, rapid-eye-movement sleep, sleep depth, and the level of airway collapse alter requirements. Laboratory polysomnography, home sleep apnea testing, device-use logs, and symptoms can jointly inform titration. An attractive tongue movement, quieter snoring, or fewer events during one hour cannot replace full-night AHI, oxygen desaturation index, hypoxic burden, and sleep-quality assessment.

Patients normally start, pause, or step stimulation only within a prescribed range. Acclimatization permits a tolerable starting level and reassessment rather than a nightly search for maximum intensity. Discomfort before sleep may call for review of start delay, accessory position, and program. Persistent late-night events require separation of interruption in use, position, REM clustering, sensing mistiming, and anatomic nonresponse. Remote advice cannot substitute for direct assessment of the wound, tongue motion, and objective sleep when those are in question.

Effectiveness endpoints, residual disease, and evidence interpretation

Evaluation should report baseline and treated AHI, oxygen desaturation index, nadir and cumulative hypoxemia, positional and sleep-stage distribution, daytime sleepiness, sleep-related quality of life, and actual use. A common definition of response permits residual events; a responder is therefore not necessarily cured and does not automatically have normalized cardiovascular risk. AHI changes with scoring rules, test night, sleep position, and the proportion of REM sleep. Results using 3-percent and 4-percent desaturation rules should not be pooled without qualification.

A 2024 synthesis of 44 studies and 8,670 participants found improvement in AHI and quality of life at one year for many carefully selected patients, with some effects maintained between 12 and 36 months. Most evidence, however, came from single-arm cohorts with different products, eligibility rules, and follow-up. A separate safety review included 17 studies and 1,962 participants, found highly heterogeneous adverse-event reporting, and disclosed industry relationships for several authors. Real-world results do not guarantee benefit to every recipient or permit the success rate of one architecture to be assigned to another.

An inadequate response can reflect airway phenotype, palatal or lateral-wall collapse, weight change, selected nerve branches, lead location, sensing timing, tolerance, or insufficient use. Significant residual OSA after optimization calls for renewed full-night assessment and consideration of PAP, an oral appliance, positional care, weight management, or another airway treatment in combination, not indefinite escalation of current. A randomized sham-controlled study did not show improvement in all cardiovascular measures despite control of respiratory events, so the implant should not be promised to lower blood pressure or prevent cardiovascular and cerebrovascular events.

Adverse effects, device failure, and procedural compatibility

Common therapy-related problems include stimulation discomfort, tongue or floor-of-mouth pain, tongue abrasion, dry mouth, sleep arousal, altered swallowing or speech, and temporary tongue weakness. Operative and hardware risks include infection, hematoma or seroma, scar pain, nerve injury, generator or implant migration, lead fracture or migration, sensing error, skin erosion, revision, and explantation. Event-reporting databases cannot establish incidence because they have underreporting, duplicates, and no reliable denominator, but they can reveal failure types not prominent in trials.

Sudden loss of benefit first calls for confirmation of actual use, external accessories, charge, patch coupling, and program, followed by implant-center review of impedance, sensed waveform, component position, and imaging. Repeated switching or large self-directed increases are unsafe substitutes. Long-term follow-up covers the wound and nerve function, objective sleep, weight, component longevity, recalls, software, and battery. Generator removal does not necessarily remove every lead; residual components continue to affect MRI and other procedures, so the device card and operative history should be retained for life.

MRI compatibility depends on the complete model set, residual components, body region, field strength, coil, position, and settings before and after scanning. “New generation” or an individual component label is insufficient. Electrosurgery, radiofrequency or microwave ablation, diathermy, radiation, defibrillation, and another implanted stimulator can cause heating, damage, or unintended stimulation. Imaging, procedural, and implant teams should coordinate using the exact instructions. An airport or security alarm is not a functional test of the device.

Nightly use, longitudinal management, and sleep safety

Implantation does not equal automatic treatment. The patient must activate therapy correctly each night. An externally powered system also requires patch placement, attachment of the energizing unit, and daytime charging; a synchronized implanted system still depends on remote operation and battery status. Logged “on time” is not necessarily time with effective stimulation and is not proof that the airway was open. Adherence review should account for pauses, signal loss, patch detachment, shutdown because of discomfort, and travel nights when an accessory was not available.

Weight, nasal resistance, alcohol and sedatives, sleep position, menopause, neurologic disease, and upper-airway surgery can change both OSA and device response. Periodic clinical review and repeat sleep testing when appropriate therefore remain necessary. Quieter snoring does not exclude residual hypoxemia, and feeling more energetic does not replace objective verification. Until treatment is shown to be adequate, precautions about sleepy driving and safety-sensitive work still apply. Recurrent witnessed apneas, morning headache, or sudden sleepiness warrants reassessment.

Device applications and cloud platforms may store sleep timing, use behavior, location, respiratory signals, and health information. Access should be limited, transmission encrypted, and remote changes audited. Children, adolescents, pregnancy, and people with multiple implants require management only under a specific indication and specialist team. Hypoglossal nerve stimulation is an option for carefully selected OSA, not a general anti-snoring implant, and it does not replace diagnosis and treatment of central apnea, obesity hypoventilation, or another sleep disorder.